TX-MAVENIR
11.3.2021 15:02:11 CET | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), announced today its extended Artificial Intelligence (AI) and Analytics portfolio to enable closed-loop automation and drive digital transformation.
AI and machine learning (ML) in mobile network infrastructure is expected to lower costs by automating functions that typically require human interaction and to speed new revenue generating service offerings, becoming increasingly important as edge, open radio access networks (Open RAN), and 5G cores get deployed.
Mavenir’s AI and Analytics portfolio includes solutions designed to analyze and derive inferences from vast amounts of unstructured data to automate networks, achieve cost savings, and build out 5G use cases. Many Industry 4.0 use cases such as Intelligent Video Analytics and AR/VR are enabled by 5G that require AI-driven inferences at the edge. Mavenir’s portfolio includes these AI-enabled applications for Network Automation, Intelligent Operations, EdgeAI, and Network Security.
1)
|
Network Automation: Mavenir’s RAN Intelligent Controller (RIC) and Network Data Analytics Function (NWDAF) follow the specifications introduced by the O-RAN Alliance and 3GPP and operate as the heart of a network automation vision. The RIC and NWDAF enable the network to dynamically adapt to traffic conditions using machine learning (ML)-based algorithms and applications that can be deployed in any network in a multi-vendor environment. Mavenir’s containerized RIC and NWDAF product capabilities include: |
|
|
2)
|
Intelligent Operations: By automating network operational processes with AI and analytics solutions, operators should be able to substantially reduce the cost and time from traditional, more labor-intensive methods such as drive testing, log inspection, troubleshooting, and manual calibration. With AI-based prediction engines, operators can achieve intelligent capacity planning and reduce the possibility of large-scale network outages. With anomaly detection capability, operators can uncover underlying network faults that are not easily visible. This AI-driven Operations (AIOps) solution using ML techniques plays a key role in reducing operating expenses and gives operators complete control over their networks. |
|
|
3)
|
5G EdgeAI : Mavenir’s 5G EdgeAI solution includes Intelligent Video Analytics that can support myriad of use cases from facial recognition to anomaly detection for smart city and industry 4.0 use cases. Next generation of AR/VR applications are accelerated and enhanced by this edge platform. Large number of sensor data gets analyzed and actions are taken in a matter of milliseconds by the edge Industrial Internet of Things (IIoT) analytics application. |
|
|
|
“AI is the key driver for Industry 4.0, providing real-time insights & control of industrial processes. Low latency, high density of 5G are also enablers, so in essence, the combination of 5G and AI = Industry 4.0,” said Kuntal Chowdhury, SVP and GM, Mavenir AI and Analytics Business Unit. “While Mavenir’s AI and Analytics solutions are now available as standalone solutions, we have been offering intelligent insights as integrated solutions to Tier 1 customers around the world for years. Currently over 200 systems are deployed in more than 80 customer networks and our solutions process and analyze billions of records per day, offering real-time/near-real-time insights to optimize network performance with little to no human intervention.” |
|
|
4)
|
Network security: As new vulnerabilities arise, Mavenir’s Fraud Management and Security Suite protect the network in real-time with predictive analytics and ML. The Real-Time Fraud Management and Security analytics is leveraging unique ML algorithms and a specifically designed framework suited to manage the volume, velocity, and variety of structured and unstructured data over wireless networks. |
|
|
|
“Mavenir Security and Anti-Fraud Solutions based on AI/ML are taking care of on-going revenue savings at Telefónica Argentina,” says Diego Quevedo, Core Network Solution Design Lead, Telefónica Argentina. “We are in close cooperation with Mavenir to ensure the up-to-date protection of our network.” |
|
|
|
“Mavenir’s approach of applying Real-Time Machine Learning technology to protect key operator services and revenue has been highly valued by customers,” said Ilia Abramov, VP and GM, Mavenir Security BU. “New threats raised in the recent years and increasing attack vectors on Mobile Network Services have been successfully detected and blocked though our installed base. The increased level of trust of our AI/ML technology has been confirmed with substantial growth in additional network implementations in the last year.” |
“Leveraging our deep AI/ML knowledge and advanced capabilities enables Communications Service Providers to optimize, automate and advance their mobile networks for the future of 5G,” said BG Kumar, President, Mavenir’s Communications Services Business Group. “Network automation and service protection driven by AI/ML are core capabilities of Mavenir and one of the highest priorities of our customers, and we are proud to provide this solution set to enable them to realize their vision.”
Mavenir’s AI/ML and Analytics solutions and Fraud/Security solutions are deployed at multiple Tier 1 operator networks across North America, EMEA, and APAC regions. Additionally, Mavenir is dedicated to continuous AI/ML innovation through the R&D Center of Excellence in Brno, Czech Republic, and R&D in Richardson TX and Bangalore, India.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation. Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack for communications service providers and enterprises. From 5G application layers (VoLTE, Messaging) to Packet Core and RAN, Security, Edge Analytics and AI, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.
Leveraging innovations in Mobile Core with IMS (VoLTE, VoWiFi, Advanced Messaging/RCS), and Packet Core (vEPC, 5G Core) as well as Radio Access/Edge (OpenRAN), Private Networks, as well as Mobile Services and Applications such as Digital Enablement. Mavenir accelerates digital network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
